Copley
This article was originally published in The Tan Sheet
Executive Summary
Daniel Karpolinski joins as CEO and president of the Canton, Mass.-based generic drug firm. Karpolinski was formerly president and CEO of CoCensys. The Copley position has not been filled since February 1997, when interim President Kenneth Larsen stepped down but remained chairman of the board. Larsen will continue as a board member; Karpolinski will become chairman. The last CEO at Copley was Gabriel Cipau, PhD, who resigned in July 1996...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning